Office of Women’s Health director named
Executive Summary
FDA names Kathleen Uhl as director of the Office of Women's Health, effective Dec. 15. Uhl has been with the Center for Drug Evaluation & Research since 1998, most recently serving as the team leader for the Pregnancy & Lactation Labeling Team in the Office of New Drugs. Uhl will replace Theresa Toigo, who took over as acting director of the women's health office after Susan Wood resigned in protest of FDA's handling of an OTC switch application for Barr's emergency contraceptive Plan B (1"The Pink Sheet" Sept. 6, 2005, p. 6)...
You may also be interested in...
Plan B Delay Draws Criticism From Congress, Academia, FDA Official
FDA's handling of Barr's application to switch Plan B over the counter could elicit heightened external scrutiny of the agency's ability to make drug approval decisions based solely on science and public health
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.